Critical Illness, gastrointestinal complications, and medication therapy during enteral feeding in critically Ill adult patients

Nutrition in Clinical Practice

Volumn 25, Issue 1, 2010, Pages 32-49

  Btaiche, Imad F ^a   Chan, Lingtak Neander ^a   Pleva, Melissa ^a   Kraft, Michael D ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Critical illness; Enteral nutrition; Gastrointestinal motility

Indexed keywords

ADRENALIN; ANTACID AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; CLONIDINE; DEXMEDETOMIDINE; DOPAMINE; FENTANYL; FUROSEMIDE; HYDROMORPHONE; LAXATIVE; LOOP DIURETIC AGENT; LOPERAMIDE; METHADONE; MORPHINE; NALMEFENE; NALOXONE; NARCOTIC ANALGESIC AGENT; NORADRENALIN; OPIATE ANTAGONIST; PHENOTHIAZINE DERIVATIVE; PHENYLEPHRINE; PROKINETIC AGENT; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; ALKALOSIS; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; CLINICAL TRIAL; CONSTIPATION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; ENTERIC FEEDING; FLUID THERAPY; GASTRIC DYSMOTILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; ILEUS; INCIDENCE; NAUSEA; NUTRITIONAL INTOLERANCE; NUTRITIONAL SUPPORT; OPTIMAL DRUG DOSE; PRIMARY PREVENTION; REVIEW; SEDATION; SINGLE DRUG DOSE; STOMACH EMPTYING; TREATMENT WITHDRAWAL; VOMITING; XEROSTOMIA;

ADULT; CRITICAL ILLNESS; ENTERAL NUTRITION; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; MALNUTRITION;

EID: 77952609207     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0884533609357565     Document Type: Review

References (191)

1. Biolo G, Grimble G, Preiser JC, et al; European Society of Intensive Care Medicine Working Group on Nutrition and Metabolism. Position paper of the ESICM Working Group on Nutrition and Metabolism. Metabolic basis of nutrition in intensive care unit patients: Ten critical questions. Intensive Care Med. 2002;28:1512-1520.
2. Daley BJ, Bistrian BR. Nutritional assessment. In: Zaloga GP, ed. Nutrition in Critical Care. St. Louis, MO: Mosby-Year Book;1994:9-33.
3. Wolfe RR. Carbohydrate metabolism in critically ill patients: implications for nutritional support. Crit Care Clin. 1987;3:11-24.
4. Schmidt H, Martindale R. The gastrointestinal tract in critical illness. Curr Opin Clin Nutr Metab Care. 2001;4:547-551.
5. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264-2270.
6. Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ. 2001;323:773-776.
7. Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P; Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr. 2003;27:355-373.
8. McClave SA, Martindale RG, Vanek VW, et al; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2009;33:277-316.
9. McClave SA, Sexton LK, Spain DA, et al. Enteral tube feeding in the intensive care unit: factors impeding adequate delivery. Crit Care Med. 1999;27:1252-1256.
10. Mallampalli A, McClave SA, Snider HL. Defining tolerance to enteral feeding in the intensive care unit. Clin Nutr. 2000;19:213-215.
11. Metheny NA, Clouse RE, Chang YH, Stewart BJ, Oliver DA, Kollef MH. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med. 2006;34:1007-1015.
12. Deane A, Chapman MJ, Fraser RJ, Bryant LK, Burgstad C, Nguyen NQ. Mechanisms underlying feed intolerance in the critically ill: implications for treatment. World J Gastroenterol. 2007;13:3909-3917.
13. Bankhead R, Boullata J, Brantley S, et al; A.S.P.E.N. Board of Directors. Enteral nutrition practice recommendations. JPEN J Parenter Enteral Nutr. 2009;33:122-167.
14. Adam S, Batson S. A study of problems associated with the delivery of enteral feed in critically ill patients in five ICUs in the UK. Intensive Care Med. 1997;23:261-266.
15. Heyland D, Cook DJ, Winder B, Brylowski L, Van deMark H, Guyatt G. Enteral nutrition in the critically ill patient: a prospective survey. Crit Care Med. 1995;23:1055-1060.
16. Mentec H, Dupont H, Bocchetti M, Cani P, Ponche F, Bleichner G. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med. 2001;29:1955-1961.
17. Montejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med. 1999;27:1447-1453.
18. Reintam A, Parm P, Kitus R, Kern H, Starkopf J. Gastrointestinal symptoms in intensive care patients. Acta Anaesthesiol Scand. 2009;53:318-324.
19. Zaloga GP. Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes. Lancet. 2006;367:1101-1111.
20. Frost P, Edwards N, Bihari D. Gastric emptying in the critically ill-the way forward? Intensive Care Med. 1997;23:243-245.
21. Martin CM, Doig GS, Heyland DK, Morrison T, Sibbald WJ; Southwestern Ontario Critical Care Research Network. Multicentre, cluster-randomized clinical trial of algorithms for critical-care enteral and parenteral therapy (ACCEPT). CMAJ. 2004;170:197-204.
22. Engel JM, Muhling J, Junger A, Menges T, Karcher B, Hempelmann G. Enteral nutrition practice in a surgical intensive care unit: what proportion of energy expenditure is delivered enterally? Clin Nutr. 2003;22:187-192.
23. Petros S, Engelmann L. Enteral nutrition delivery and energy expenditure in medical intensive care patients. Clin Nutr. 2006; 25:51-59.
24. O'Meara D, Mireles-Cabodevila E, Frame F, et al. Evaluation of delivery of enteral nutrition in critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008;17:53-61.
25. Elpern EH, Stutz L, Peterson S, et al. Outcomes associated with enteral tube feedings in a medical intensive care unit. Am J Crit Care. 2004;13:221-227.
26. O'Leary-Kelley CM, Puntillo KA, Barr J, et al. Nutritional adequacy in patients receiving mechanical ventilation who are fed enterally. Am J Crit Care. 2005;14:222-231.
27. Villet S, Chiolero RL, Bollmann MD, et al. Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clin Nutr. 2005;24:502-509.
28. Rubinson L, Diette GB, Song X, Brower RG, Krishnan JA. Low caloric intake is associated with nosocomial bloodstream infections in patients in the medical intensive care unit. Crit Care Med. 2004;32:350-357.
29. Hsu CW, Sun SF, Lin SL, et al. Duodenal versus gastric feeding in medical intensive care unit patients: a prospective, randomized, clinical study. Crit Care Med. 2009;37:1866-1872.
30. Marik PE, Zaloga GP. Gastric versus post-pyloric feeding: a systematic review. Crit Care. 2003;7:R46-R51.
31. Rohm KD, Boldt J, Piper SN. Motility disorders in the ICU: recent therapeutic options and clinical practice. Curr Opin Clin Nutr Metab Care. 2009;12:161-167.
32. Herbert MK, Holzer P. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients; current status and future options. Clin Nutr. 2008;27:25-41.
33. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23:407-423.
34. Ritz MA, Fraser R, Edwards N, et al. Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test. Crit Care Med. 2001;29:1744-1749.
35. Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med. 1996;22:1339-1344.
36. Kao CH, ChangLai SP, Chieng PU, Yen TC. Gastric emptying in head-injured patients. Am J Gastroenterol. 1998;93:1108-1112.
37. Ott L, Young B, Phillips R, et al. Altered gastric emptying in the head-injured patient: Relationship to feeding intolerance. J Neurosurg. 1991;74:738-742.
38. Norton JA, Ott LG, McClain C, et al. Intolerance to enteral feeding in brain-injured patients. J Neurosurg. 1988;68:62-66.
39. Cook AM, Peppard A, Magnuson B. Nutrition considerations in traumatic brain injury. Nutr Clin Pract. 2008;23:608-620.
40. Landzinski J, Kiser TH, Fish DN, Wischmeyer PE, MacLaren R. Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr. 2008;32:45-50.
41. Nguyen NQ, Chapman M, Fraser RJ, Bryant LK, Burgstad C, Holloway RH. Prokinetic therapy for feed intolerance in critical illness: one drug or two? Crit Care Med. 2007;35:2561-2567.
42. Mostafa SM, Bhandari S, Ritchie G, Gratton N, Wenstone R. Constipation and its implications in the critically ill patient. Br J Anaesth. 2003;91:815-819.
43. Patanwala AE, Abarca J, Huckleberry Y, Erstad BL. Pharmacologic management of constipation in the critically ill patient. Pharmacotherapy. 2006;26:896-902.
44. Asai T. Constipation: does it increase morbidity and mortality in critically ill patients? Crit Care Med. 2007;35:2861-2862. (Pubitemid 350175790)
45. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001;182(5A suppl):3S-10S.
46. Ferraz AA, Cowles VE, Condon RE, et al. Nonopioid analgesics shorten the duration of postoperative ileus. Am Surg. 1995;61: 1079-1083.
47. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000;87:1480-1493.
48. Ceppa EP, Fuh KC, Bulkley GB. Mesenteric hemodynamic response to circulatory shock. Curr Opin Crit Care. 2003;9:127-132.
49. Jakob SM, Merasto-Minkkinen M, Tenhunen JJ, Heino A, Alhava E, Takala J. Prevention of systemic hyperlactatemia during splanchnic ischemia. Shock. 2000;14:123-127.
50. Kreimeier U. Pathophysiology of fluid imbalance. Crit Care. 2000;4(suppl 2):S3-S7.
51. Martikainen TJ, Tenhunen JJ, Giovannini I, Uusaro A, Ruokonen E. Epinephrine induces tissue perfusion deficit in porcine endotoxin shock: evaluation by regional CO(2) content gradients and lactate-to-pyruvate ratios. Am J Physiol Gastrointest Liver Physiol. 2005;288:G586-G592.
52. Creteur J, De Backer D, Sun Q, Vincent JL. The hepatosplanchnic contribution to hyperlactatemia in endotoxic shock: effects of tissue ischemia. Shock. 2004;21:438-443.
53. Fruhwald S, Holzer P, Metzler H. Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact. Intensive Care Med. 2007;33:36-44.
54. Safavi M, Honarmand A. Admission hypomagnesemia; impact on mortality or morbidity in critically ill patients. Middle East J Anesthesiol. 2007;19:645-660.
55. Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care. 2008;12:R162.
56. Beal AL, Scheltema KE, Beilman GJ, Deuser WE. Hypokalemia following trauma. Shock. 2002;18:107-110.
57. Chen JZ, Deng AW, Xu JF. Electroenterogram manifestations and significance in hypokalemia. Di Yi Jun Yi Da Xue Xue Bao. 2005;25:7-9.
58. DeSchepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383-394.
59. De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69:103-115.
60. Tittle M, McMillan SC. Pain and pain-related side effects in an ICU and on a surgical unit: nurses' management. Am J Crit Care. 1994;3:25-30.
61. Breitfeld C, Peters J, Vockel T, et al. Emetic effects of morphine and piritramide. Br J Anaesth. 2003;91:218-223.
62. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustainedrelease hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737-743.
63. Weschules DJ, Bain KT, Reifsnyder J, et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustainedrelease morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med. 2006;7:320-329.
64. Fruhwald S, Scheidl S, Toller W, et al. Low potential of dobutamine and dopexamine to block intestinal peristalsis as compared with other catecholamines. Crit Care Med. 2000;28:2893-2897.
65. Dive A, Foret F, Jamart J, Bulpa P, Installe E. Effect of dopamine on GI motility during critical illness. Intensive Care Med. 2000;26:901-907.
66. Lin HC, Neevel C, Chen PS, Suh G, Chen JH. Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway. Am J Physiol Gastrointest Liver Physiol. 2003;285:G1310-G1316.
67. Tomita R, Tanjoh K, Fujisaki S, Ikeda T, Fukuzawa M. Regulation of the enteric nervous system in the colon of patients with slow transit constipation. Hepatogastroenterology. 2002;49:1540-1544.
68. Anderson G, Noorian AR, Taylor G, et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol. 2007;207:4-12.
69. Sundaram U. Mechanism of intestinal absorption: effect of clonidine on rabbit ileal villus and crypt cells. J Clin Invest. 1995;95:2187-2194.
70. Mach T. The brain-gut axis in irritable bowel syndrome--clinical aspects. Med Sci Monit. 2004;10:RA125-RA131.
71. Buchman AL, Fryer J, Wallin A, Ahn CW, Polensky S, Zaremba K. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr. 2006;30:487-491.
72. Asai T, Mapleson WW, Power I. Differential effects of clonidine and dexmedetomidine on gastric emptying and gastrointestinal transit in the rat. Br J Anaesth. 1997;78:301-307. (Pubitemid 27099922)
73. Herbert MK, Roth-Goldbrunner S, Holzer P, Roewer N. Clonidine and dexmedetomidine potently inhibit peristalsis in the guinea pig ileum in vitro. Anesthesiology. 2002;97:1491-1499.
74. Memiş D, Dökmeci D, Karamanlioǧlu B, Turan A, Türe M. A comparison of the effect on gastric emptying of propofol or dexmedetomidine in critically ill patients: preliminary study. Eur J Anaesthesiol. 2006;23:700-704.
75. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009; 13:R75.
76. Wunsch H, Kahn JM, Kramer AA, Rubenfeld GD. Use of intravenous infusion sedation among mechanically ventilated patients in the United States. Crit Care Med. 2009;37:3031-3039.
77. Kato J, Ogawa Y, Kojima W, Aoki K, Ogawa S, Iwasaki K. Cardiovascular reflex responses to temporal reduction in arterial pressure during dexmedetomidine infusion: a double-blind, randomized, and placebocontrolled study. Br J Anaesth. 2009;103:561-565.
78. Stewart RM, Park PK, Hunt JP, et al; National Institutes of Health/ National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring. J Am Coll Surg. 2009;208:725-735.
79. Sakr Y, Vincent JL, Reinhart K, et al; Sepsis Occurrence in Acutely Ill Patients Investigators. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest. 2005;128:3098-3108.
80. Ryan MP. Interrelationships of magnesium and potassium homeostasis. Miner Electrolyte Metab. 1993;19:290-295.
81. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18:2649-2652.
82. Cali RL, Meade PG, Swanson MS, Freeman C. Effect of morphine and incision length on bowel function after colectomy. Dis Colon Rectum. 2000;43:163-168.
83. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48-53.
84. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992;52:90-95.
85. Sykes N. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135-144.
86. Latasch L, Zimmermann M, Eberhardt B, Jurna I. Treament of morphine-induced constipation with oral naloxone. Anaesthesist. 1997;46:191-194.
87. Mixides G, Liebl MG, Bloom K. Enteral administration of naloxone for treatment of opioid-associated intragastric feeding intolerance. Pharmacotherapy. 2004;24:291-294.
88. Meissner W, Dohrn B, Reinhart K. Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Crit Care Med. 2003;31:776-780.
89. Tofil NM, Benner KW, Faro SJ, Winkler MK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatr Crit Care Med. 2006;7:252-354.
90. Thomas MC, Erstad BL. Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation. Am J Health Syst Pharm. 2003;60:1264-1267.
91. Arpino PA, Thompson BT. Safety of enteral naloxone for the reversal of opiate-induced constipation in the intensive care unit. J Clin Pharm Ther. 2009;34:171-175.
92. Simpkin JN, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther. 1988;244:195-205.
93. Cheskin LJ, Chami TN, Johnson RE, Jaffe JH. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. 1995;39:151-154.
94. Büchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312-325.
95. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098-1105.
96. Delaney CP, Wolff BG, Viscusi ER, et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg. 2007;245:355-363.
97. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid- induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343.
98. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;(2):CD006332.
99. Relistor [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2008.
100. Progenics Pharmaceuticals, Inc. Wyeth Pharmaceuticals, Inc. Wyeth and Progenics announce preliminary clinical trial results for Relistor oral and intravenous formulations [press release]; 2008.
101. Entereg [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
102. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206.
103. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction. A 21-day treatment randomized clinical trial. J Pain. 2005;6:184-192.
104. GlaxoSmithKline and Adolor Corporation. GlaxoSmithKline and Adolor report top line results from phase 3 studies of Alvimopan [press release]; 2006.
105. GlaxoSmithKline and Adolor Corporation. GSK and Adolor announce preliminary results from Phase 3 Safety study of Alvimopan (Entereg/Entrareg) [press release]; 2007.
106. Adolor Corporation. Entereg (alvimopan) capsules for postoperative ileus. US FDA Advisory Committee Briefing Document. http:// www.fda.gov/ohrms/DOCKETS/ ac/08/briefing/2008- 4336b1- 02-Adolor.pdf. Accessed June 8, 2009.
107. Adolor Corporation. Entereg (alvimopan) Capsules for Postoperative Ileus. U.S. FDA Advisory Committee Briefing Document. http://www.fda.gov/ohrms/ DOCKETS/ac/08/briefing/2008-4336b1- 02-Adolor.pdf. Accessed Aug 9, 2009.
108. Law NM, Bharucha AE, Undale AS, et al. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1228-G1237.
109. De Giorgio R, Knowles CH. Acute colonic pseudo-obstruction. Br J Surg. 2009;96:229-239.
110. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005;22:917-925.
111. Saunders MD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol. 2007;21:671-687.
112. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137-141.
113. Paran H, Silverberg D, Mayo A, Shwartz I, Neufeld D, Freund U. Treatment of acute colonic pseudo-obstruction with neostigmine. J Am Coll Surg. 2000;190:315-318.
114. Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:599-603.
115. Althausen PL, Gupta MC, Benson DR, Jones DA. The use of neostigmine to treat postoperative ileus in orthopedic spinal patients. J Spinal Disord. 2001;14:541-545.
116. Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-268.
117. Mehta R, John A, Nair P, et al. Factors predicting successful outcome following neostigmine therapy in acute colonic pseudoobstruction: a prospective study. J Gastroenterol Hepatol. 2006;21:459-461.
118. Loftus CG, Harewood GC, Baron TH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol. 2002;97:3118-3122.
119. van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, Bosman RJ, Zandstra DF. Neostigmine resolves critical illnessrelated colonic ileus in intensive care patients with multiple organ failure. A prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001;27:822-827.
120. Foxx-Orenstein AE, McNally MA, Odunsi ST. Update on constipation: one treatment does not fit all. Cleve Clin J Med. 2008;75:813-824.
121. Ghoshal UC. Review of pathogenesis and management of constipation. Trop Gastroenterol. 2007;28:91-95.
122. Fan LL, Graham LM. Radiological cases of the month. Lipoid pneumonia from mineral oil aspiration. Arch Pediatr Adolesc Med. 1994;148:205-206.
123. Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics. 1999;103:E19.
124. Zanetti G, Marchiori E, Gasparetto TD, Escuissato DL, Soares Souza A Jr. Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients. Pediatr Radiol. 2007;37:1135-1139.
125. Meltzer E, Guranda L, Vassilenko L, Krupsky M, Steinlauf S, Sidi Y. Lipoid pneumonia: a preventable complication. Isr Med Assoc J. 2006;8:33-35.
126. Van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, van Roon EN, Zandstra DF, van der Voort PH. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med. 2007;35:2726-2731.
127. Patanwala AE, Abarca J, Huckleberry Y, Erstad BL. Pharmacologic management of constipation in the critically ill patient. Pharmacotherapy. 2006;26:896-902.
128. Spruill WJ, Wade WE. Diarrhea, constipation, and irritable bowel syndrome. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. http://www. accesspharmacy.com.proxy.lib.umich.edu/content .aspx?aID=3192833.
129. Benya R, Layden TJ, Mobarhan S. Diarrhea associated with tube feeding: the importance of using objective criteria. Clin Gastroenterol. 1991;13:167-172.
130. Guenter PA, Settle RG, Perlmutter S, Marino PL, DeSimone GA, Rolandelli RH. Tube feeding-related diarrhea in acutely ill patients. JPEN J Parenter Enteral Nutr. 1991;15:277-280.
131. Kelly TWJ, Patrick MR, Hillman KM. Study of diarrhea in critically ill patients. Crit Care Med. 1983;11:7-9.
132. Bliss DZ, Guenter PA, Settle RG. Defining and reporting diarrhea in tube-fed patients, what a mess! Am J Clin Nutr. 1992;55:753-759.
133. Baldi F, Bianco MA, Nardone G, Pilotto A, Zamparo E. Focus on acute diarrhoeal disease. World J Gastroenterol. 2009;15:3341-3348.
134. Sabol VK, Carlson KK. Diarrhea: applying research to bedside practice. AACN Adv Crit Care. 2007;18:32-44.
135. Weisen P, van Gossum A, Preiser JC. Diarrhoea in the critically ill. Curr Opin Crit Care. 2006;12:149-154.
136. Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: Feeding formula not necessarily the cause. Am J Med. 1990;88:91-93.
137. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
138. Bartlett JG. Narrative review: The new epidemic of clostridium difficile- associated enteric disease. Ann Intern Med. 2006;145:758-764.
139. Imhoff A, Karpa K. Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent epidodes? Nutr Clin Pract. 2009;24:15-32.
140. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton-pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33-38.
141. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridiu difficile-associated disease. JAMA. 2005;294:2989-2995.
142. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health-Syst Pharm. 2007;64:2359-2363.
143. Beaulieu M, Williamson D, Pichette G, Lachaine J. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1305-1307.
144. Modena S, Bearelly D, Swartz K, Friedenberg FK. Clostridium difficile among hospitalized patients receiving antibiotics: a casecontrol study. Infect Control Hosp Epidemiol. 2005;26:685-690.
145. Vesta KS, Wells PG, Gentry CA, Stipek WJ. Specific risk factors for Clostridium difficile-associated diarrhea: A prospective, multicenter, case control evaluation. Am J Infect Control. 2005;33:469-472.
146. Bliss DZ, Johnson S, Savik K, Clabots C, Willard K, Gerding DN. Acquisition of Clostridium difficile and clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med. 1998;129:1012-1019.
147. Zilberberg MD, Shorr AF, Micek ST, Doherty JA, Kollef MH. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583-2589.
148. Musher DM, Aslam S. Treatment of clostridium difficile colitis in the critical care setting. Crit Care Clin. 2008;24:279-291.
149. Cunha BA. Nosocomial diarrhea. Crit Care Clin. 1998;14:329-338.
150. Van der Spoel JI, Schultz MJ, van der Voort PHJ, de Jonge E. Influence of severity of illness, medication and selective decontamination on defecation. Intensive Care Med. 2006;32:875-880.
151. Ferrie S, East V. Managing diarrhoea in intensive care. Aust Crit Care. 2007;20:7-13.
152. Dickerson RN, Melnik G. Osmolality of oral drug solutions and suspensions. Am J Hosp Pharm. 1988;45:832-834.
153. Johnston KR, Govel LA, Andritz MH. Gastrointestinal effects of sorbitol as an additive in liquid medications. Am J Med. 1994;97:185-191.
154. Miller SJ, Oliver AD. Sorbitol content of selected sugar-free liquid medications. Hosp Pharm. 1993;28:741-744, 755.
155. Lutomski DM, Gora ML, Wright SM, Martin JE. Sorbitol content of selected oral liquids. Ann Pharmacother. 1993;27:269-274.
156. Hyams JS. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterology. 1983;84:30-33.
157. Scarlett Y. Medical management of fecal incontinence. Gastroenterology. 2004;126(1 suppl 1):S55-S63.
158. Ericsson CD, Evans DG, DuPont HL, Evans DJ Jr, Pickering LK. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J Infect Dis. 1977;136:693-696.
159. Burke V, Gracey M. Effects of salicylate on intestinal absorption: in vitro and in vivo studies with enterotoxigenic micro-organisms. Can J Comp Med. 1978;42:260-268.
160. Gyles CL, Zigler M. The effect of adsorbant and anti-inflammatory drugs on secretion in ligated segments of pig intestine infected with Escherichia coli. Can J Comp Med. 1978;42:260-268.
161. Soriano-Brücher H, Avendaño P, O'Ryan M, et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics. 1991;87:18-27.
162. Pickering LK, Feldman S, Ericsson CD, Cleary TG. Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J Pediatr. 1981;99:654-656.
163. DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med. 1990;88: 15S-19S.
164. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents. 2009;33:4-7.
165. Cholestyramine for oral suspension, USP light package insert. Laurelton, NY: Eon Labs Manufacturing; 2000.
166. Steevens EC, Lipscomb AF, Poole GV, Sacks GS. Comparison of continuous vs intermittent nasogastric enteral feeding in trauma patients: Perceptions and practice. Nutr Clin Pract. 2002;17: 118-122.
167. Shang E, Geiger N, Sturm JW, Post S. Pump-assisted versus gravity- controlled enteral nutrition in long-term percutaneous endoscopic gastrostomy patients: a prospective controlled trial. JPEN J Parenter Enteral Nutr. 2003;27:216-219.
168. Lee JS, Auteung TW. A comparison of two feeding methods in the alleviation of diarrhoea in older tube-fed patients: a randomized controlled trial. Age Ageing. 2003;32:388-393.
169. Parrish CR. Enteral feeding: the art and the science. Nutr Clin Pract. 2003;18:76-85.
170. Barrett JS, Shepherd SJ, Gibson PR. Strategies to manage gastrointestinal symptoms complicating enteral feeding. JPEN J Parenter Enteral Nutr. 2009;33:21-26.
171. Schneider SM, Girard-Pipau F, Anty R, et al. Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clin Nutr. 2006;25:82-90.
172. Marian M, Carlson SJ. Enteral formulations. In: Merritt R, ed. The A.S.P.E.N. Nutrition Support Practice Manual. 2nd ed. Silver Spring, MD: The American Society for Parenteral and Enteral Nutrition; 2005:63-75.
173. Todd PA, Benfield P, Goa KL. Guar gum: A review of its pharmacological properties, and use as a dietary adjunct in hypercholesterolaemia. Drugs. 1990;39:917-928.
174. Elia M, Engfer MB, Green CJ, Sikl DBA. Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae. Aliment Pharmacol Ther. 2008;27:120-145.
175. Spapen H, Diltoer M, van Malderen C, Opdenacker G, Suys E, Huyghens L. Soluble fiber reduces the incidence of diarrhea in septic patients receiving total enteral nutrition: a prospective, double-blind, randomized, and controlled trial. Clin Nutr. 2001; 20:301-305.
176. Rushdi TA, Pichard C, Khater YH. Control of diarrhea by fiberenriched diet in ICU patients on enteral nutrition: a prospective randomized controlled trial. Clin Nutr. 2004;23:1344-1352.
177. Yang G, Wu XT, Zhou Y, Wang YL. Application of dietary fiber in clinical enteral nutrition: a meta-analysis of randomized controlled trials. World J Gastroenterol. 2005;11:3935-3938.
178. Rohde CL, Bartolini V, Jones N. The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract. 2009;24:33-40.
179. Bengmark S. Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metab Care. 2001;4:571-579.
180. Koretz RL. Probiotics, critical illness, and methodologic bias. Nutr Clin Pract. 2009;24:45-49.
181. Salminen MK, Rautelin J, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-69.
182. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634.
183. Cassone M, Serra P, Mondello F, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J Clin Microbiol. 2003;41:5340-5343.
184. Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651-659.
185. Manzanares W, Hardy G. The role of prebiotics and synbiotics in critically ill patients. Curr Opin Clin Nutr Metab Care. 2008;11:782-789.
186. Kreymann KG, Berger MM, Deutz NE, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr. 2006;25:210-223.
187. Spain DA, McClave SA, Sexton LK, et al. Infusion protocol improves delivery of enteral tube feeding in the critical care unit. JPEN J Parenter Enteral Nutr. 1999;23:288-292.
188. Doig GS, Simpson F, Finfer S, et al; Nutrition Guidelines Investigators of the ANZICS Clinical Trials Group. Effect of evidence- based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. JAMA. 2008;300:2731-2741.
189. Chapman G, Curtas S, Meguid MM. Standardized enteral orders attain caloric goals sooner: a prospective study. JPEN J Parenter Enteral Nutr. 1992;16:149-151.
190. Heyland DK, Dhaliwal R, Day A, Jain M, Drover J. Validation of the Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients: results of a prospective observational study. Crit Care Med. 2004;32:2260-2266.
191. Miller CA, Grossman S, Hindley E, MacGarvie D, Madill J. Are enterally fed ICU patients meeting clinical practice guidelines? Nutr Clin Pract. 2008;23:642-650. Downloaded